WASHINGTON (Reuters) – An appeals court on Monday upheld a judge’s decision dismissing a lawsuit filed by the U.S. Federal Trade Commission to fight the practice of brand-name drug companies using a government petition system to delay cheaper, generic drugs from coming to market.
The 3rd U.S. Circuit Court of Appeals ruled that a federal court in Delaware had been correct in dismissing the FTC’s lawsuit against Shire. Shire was acquired by Takeda Pharmaceutical Co last month.
Agency - ViroPharma - Shire - Petitions - Filings
The agency had objected to ViroPharma, which Shire acquired in 2014, filing 46 “citizen petitions” and other filings between 2006 and 2012 to the...
Wake Up To Breaking News!
How's that peak oil working out for you?